China Lanreotide Peptide Powder (INN) for Neuroendocrine Tumors
Lanreotide powder
(INN) is a medication used in the management of acromegaly and symptoms
caused by neuroendocrine tumors, most notably carcinoid syndrome.
Lanreotide is used in the treatment of acromegaly, due to both pituitary
and non-pituitary growth hormone-secreting tumors, and the management
of symptoms caused by neuroendocrine tumors, particularly carcinoid
tumors and VIPomas. In the United States and Canada, lanreotide is only
indicated for the treatment of acromegaly. In the United Kingdom, it is
also indicated in the treatment of thyrotrophic adenoma,a rare tumor of
the pituitary gland which secretes TSH.
Lanreotide also shows activity against non-endocrine tumors, and, along
with other somatostatin analogues, is being studied as a possible
general antitumor agent.
Synonyms:LANREOTIDE;AUTOGEL;BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR
AMIDE;BIM-23014;ANGIOPEPTIN;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2,
(DISULFIDE BOND);IPSTYL
CAS:108736-35-2
MF:C54H69N11O10S2
MW:1096.32
Product Categories:hormones
storage temp. :20°C
Chemical Properties:White to off-white lyophilised powder
Lanreotide Introduction:
Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and
marketed under the trade name Somatuline. It is available in several
countries, including the United Kingdom, Australia and Canada, and was
approved for sale in the United States by the Food and Drug
Administration (FDA) on August 30, 2007.
Lanreotide Indications
Lanreotide is used in the treatment of acromegaly, due to both pituitary
and non-pituitary growth hormone-secreting tumors, and the management
of symptoms caused by neuroendocrine tumors, particularly carcinoid
tumors and VIPomas. In the United States and Canada, lanreotide is only
indicated for the treatment of acromegaly. In the United Kingdom, it is
also indicated in the treatment of thyrotrophic adenoma, a rare tumor
of the pituitary gland which secretes.
Lanreotide also shows activity against non-endocrine tumors, and, along
with other somatostatin analogues, is being studied as a possible
general antitumor agent.
Lanreotide ,In Dec 2014 the US FDA approved lanreotide for the treatment
of patients with unresectable, well or moderately differentiated,
locally advanced or metastatic gastroenteropancreatic neuroendocrine
tumors (GEP-NETs).
